X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (138) 138
index medicus (138) 138
female (131) 131
middle aged (89) 89
aged (75) 75
adult (71) 71
oncology (65) 65
abridged index medicus (50) 50
obstetrics & gynecology (44) 44
chemotherapy (40) 40
ovarian neoplasms - drug therapy (38) 38
cancer (35) 35
antineoplastic combined chemotherapy protocols - therapeutic use (30) 30
aged, 80 and over (29) 29
neoplasm staging (29) 29
prognosis (28) 28
carcinoma (22) 22
cisplatin (21) 21
cisplatin - administration & dosage (21) 21
ovarian neoplasms - pathology (21) 21
drug evaluation (20) 20
combined modality therapy (19) 19
drug administration schedule (18) 18
antineoplastic combined chemotherapy protocols - adverse effects (17) 17
cisplatin - adverse effects (16) 16
uterine cervical neoplasms - drug therapy (16) 16
therapy (15) 15
disease-free survival (14) 14
ovarian cancer (14) 14
adenocarcinoma - drug therapy (13) 13
adenocarcinoma - pathology (13) 13
uterine neoplasms - drug therapy (13) 13
carcinoma, squamous cell - drug therapy (12) 12
care and treatment (12) 12
endometrial cancer (12) 12
prospective studies (12) 12
uterine neoplasms - pathology (12) 12
antineoplastic agents - therapeutic use (11) 11
lymphatic metastasis (11) 11
neoplasm recurrence, local - drug therapy (11) 11
survival rate (11) 11
carcinoma - drug therapy (10) 10
doxorubicin - administration & dosage (10) 10
endometrial neoplasms - drug therapy (10) 10
endometrial neoplasms - pathology (10) 10
neoplasm recurrence, local (10) 10
ovarian neoplasms - surgery (10) 10
antineoplastic agents - adverse effects (9) 9
dose-response relationship, drug (9) 9
ovarian neoplasms - mortality (9) 9
paclitaxel (9) 9
retrospective studies (9) 9
risk factors (9) 9
tumors (9) 9
cisplatin - therapeutic use (8) 8
clinical trials (8) 8
clinical trials as topic (8) 8
cyclophosphamide (8) 8
cyclophosphamide - administration & dosage (8) 8
doxorubicin (8) 8
hematology, oncology and palliative medicine (8) 8
hysterectomy (8) 8
obstetrics and gynecology (8) 8
paclitaxel - administration & dosage (8) 8
research (8) 8
survival analysis (8) 8
time factors (8) 8
treatment outcome (8) 8
adenocarcinoma (7) 7
analysis (7) 7
antineoplastic agents (7) 7
doxorubicin - adverse effects (7) 7
nausea - chemically induced (7) 7
ovarian neoplasms - therapy (7) 7
piperazines - therapeutic use (7) 7
pregnancy (7) 7
radiotherapy (7) 7
surgery (7) 7
thrombocytopenia - chemically induced (7) 7
adenocarcinoma - mortality (6) 6
age factors (6) 6
antimitotic agents (6) 6
carcinoma - pathology (6) 6
carcinoma, squamous cell - pathology (6) 6
cervical cancer (6) 6
double-blind method (6) 6
gynecologic-oncology-group (6) 6
leukopenia - chemically induced (6) 6
male (6) 6
neoplasms - drug therapy (6) 6
pilot projects (6) 6
radiation (6) 6
uterine neoplasms - surgery (6) 6
vulvar neoplasms - pathology (6) 6
abdomen (5) 5
adenocarcinoma - surgery (5) 5
article (5) 5
books (5) 5
carcinoma - mortality (5) 5
carcinoma, squamous cell - radiotherapy (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gynecologic Oncology, ISSN 0090-8258, 07/2019, Volume 154, Issue 1, p. 13
To determine if the addition of paclitaxel (P) to cisplatin and doxorubicin (CD) following surgical debulking and volume-directed radiation therapy improved... 
Anthracyclines | Relapse | Endometrial cancer | Patient outcomes | Oncology, Experimental | Radiation | Research | Diseases | Chemotherapy | Operating systems | Analysis | Diagnosis | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2011, Volume 365, Issue 26, pp. 2473 - 2483
Incorporating bevacizumab in a chemotherapy regimen (7.5 mg/kg every 3 weeks for five or six cycles) and then continuing bevacizumab alone for a total of 12... 
ANTIANGIOGENIC THERAPY | MEDICINE, GENERAL & INTERNAL | ASCITES | SOLID TUMORS | FACTOR EXPRESSION | PHASE-II | MONOCLONAL-ANTIBODY | PROGNOSTIC-SIGNIFICANCE | TUMOR ANGIOGENESIS | CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Ovarian Neoplasms - mortality | Bevacizumab | Young Adult | Neoplasms, Glandular and Epithelial - mortality | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Paclitaxel - administration & dosage | Angiogenesis Inhibitors - adverse effects | Ovarian Neoplasms - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Carboplatin - administration & dosage | Combined Modality Therapy | Neoplasms, Glandular and Epithelial - surgery | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Survival Analysis | Carcinoma, Ovarian Epithelial | Quality of Life | Aged | Ovarian Neoplasms - surgery | Drugs | Dose-response relationship (Biochemistry) | Product/Service Evaluations | Drug therapy | Ovarian cancer | Intravenous administration | Body weight | Cancer therapies | Survival | Patients | Angiogenesis | Chemotherapy | Surgery | Paclitaxel | Monoclonal antibodies | Carboplatin | Vascular endothelial growth factor | Cancer | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2008, Volume 112, Issue 3, pp. 543 - 552
Journal Article
International Journal of Gynecologic Cancer, ISSN 1048-891X, 05/2010, Volume 20, Issue 4, pp. 561-563 - 563
Journal Article
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2015, Volume 139, Issue 1, pp. 17 - 22
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2012, Volume 128, Issue 3, pp. 573 - 578
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 12, pp. 1210 - 1217
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2019, Volume 37, Issue 26, pp. JCO.19.01009 - 2328
PURPOSEWe report the final, protocol-specified analysis of overall survival (OS) in GOG-0218, a phase III, randomized trial of bevacizumab in women with newly... 
Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 10/1987, Volume 60, Issue S8, pp. 2035 - 2041
The surgical pathologic features of 621 patients with Stage I carcinoma of the endometrium are presented. All patients were treated with primary surgery... 
Prognosis | Uterine Neoplasms - surgery | Neoplasm Invasiveness | Uterine Neoplasms - pathology | Humans | Risk Factors | Female | Lymphatic Metastasis | Index Medicus | Abridged Index Medicus
Journal Article